The aim of this study was to determine the hospital survival of patients receiving high doses of catecholamines. A retrospective observational study was conducted in a 22-bed multidisciplinary adult intensive care unit of a tertiary referral university hospital. All patients (n=64) receiving >100 μg/min of adrenaline or noradrenaline or adrenaline and noradrenaline combined over a one-year period were studied to determine survival to intensive care unit and hospital discharge. Four patients survived to intensive care unit discharge and hospital discharge (6.25%, 95% CI 0.3 to 12.2%). Survival was 3.3% (95% CI 0 to 7.9%) in the subgroup of 60 patients who received >100 μg/min noradrenaline and 3.6% (95% CI 0 to 8.6%) in the 55 patients who received >2 μg/kg/min noradrenaline. None of the 32 patients who received >200 μg/min noradrenaline survived.
The requirement for high doses of vasopressors is often considered both a poor prognostic sign and an indication of catecholamine resistance [1] [2] [3] [4] [5] [6] . Anecdotally, many intensivists do not increase noradrenaline dose above 100 µg/min on the basis that doing so is futile. While there undoubtedly is an association between higher doses and worse outcome [1] [2] [3] [4] [5] , there are few data on the outcome of patients receiving very high doses. Benbenishty et al reviewed the charts of all 689 patients admitted to an intensive care unit (ICU) in a one-year period, identifying those who received any vasopressor for at least one hour. All patients who received more than 2 µg/kg/min of adrenaline or noradrenaline died 7 . Martin et al reported a 55% 28 day survival in 57 patients receiving a mean (standard deviation) maximal dose of 2.27 (2.1) µg/kg/min 8 . However the authors gave no indication of the relationship between survival and maximal dose in individual patients.
In view of the limited data, we performed a retrospective cohort study to determine the outcome of patients receiving high doses of vasopressor.
MATERIALS AND METHODS
Approval for the study was obtained from the Clinical Ethics Research Committee of the Chinese University of Hong Kong, who waived the need for informed consent, given the purely observational nature of the study. The case notes and charts of all patients admitted to the 22-bed adult ICU of a tertiary referral university hospital over a 12-month period were reviewed to identify all patients who received >100 µg/min of noradrenaline or adrenaline, or noradrenaline and adrenaline combined. In our ICU, supportive management of hypotension was to first resuscitate the patient with fluid. If the patient remained hypotensive, a noradrenaline infusion was usually started and titrated to achieve a mean arterial pressure of 65 to 80 mmHg. Other vasopressors and inotropes were added at the discretion of the physician managing the patient. The patient was considered unresponsive to catecholamines when a doubling of the infusion rate had no desirable clinical effect. Limitation of therapy was usually discussed with the patient's relatives if the patient reached this point or if the severity of multi-organ failure was such that continued treatment was considered futile. All patients with septic shock received hydrocortisone 100 mg eight hourly. Cardiac output monitoring was rarely used and the diagnosis of the type of shock was predominantly based on clinical criteria, supplemented when considered necessary, by echocardiography.
The following data were extracted from the notes and charts of all patients who met the inclusion criteria: age, gender, weight, admission diagnosis, type of shock, APACHE II score, multi-organ dysfunction (MOD) score, use of additional vasopressor, requirement for renal replacement therapy, fluid balance, length of ICU stay and ICU and hospital mortality. ICU mortality was considered the primary outcome. In addition, the following data related to catecholamine infusion were recorded: maximum dose, total time that dose exceeded 100 µg/min. For those patients who died, the presence or absence of limitation of life support therapy was recorded.
STATISTICS
Categorical data were compared using Fisher's exact test and ordinal data using the Mann-Whitney U test. A P value <0.05 (two-tailed) was considered significant.
RESULTS
During the 12-month period there were 1125 admissions to the ICU. Of these, 64 patients met the inclusion criteria. Demographic data are given in Table 1 . Four patients survived to ICU discharge and hospital discharge (6.25%, 95% CI 0.3 to 12.2%). Details of these four patients are given in Table 2 . Survival was 3.3% (95% CI 0 to 7.9%) in the subgroup of 60 patients who received >100 µg/min noradrenaline and 3.6% (95% CI 0 to 8.6%) in the 55 patients who received >2 µg/kg/min noradrenaline. None of the patients who received >200 µg/min noradrenaline (n=32) or who required >100 µg/min for more than 20 hours (n=12) survived. The highest dose of noradrenaline administered was 1587 µg/min (32.6 µg/kg/min). Seventeen patients received adrenaline (median peak dose 120 µg/min, IQR 72 to 320 µg/min) in addition to noradrenaline. Of these, two survived ( Table 2 ). None of the seven 
DISCUSSION
Our data indicate that the outcome of patients requiring high dose vasopressor therapy is poor but not as poor as the outcome reported by Benbenishty et al 7 . The hospital survival of patients receiving a combined dose of noradrenaline and adrenaline >100 µg/min was 6.25%, while in those patients receiving >2 µg/kg/min of noradrenaline the survival rate was 3.6%. Whether the low survival rate meets definitions of futility is debatable and will depend on one's definition of futility. This definition varies considerably amongst physicians, ranging from 0 to 60% chance of survival with clustering around 5% 9 . Schneiderman et al suggest this figure should be ≤1% 10 . Regardless of the definition of futility, many specialists would provide intensive care to patients with an estimated chance of survival <5% 11 .
No patient who required >200 µg/min of noradrenaline or who required >100 µg/min for more than 20 hours survived. However, the numbers of patients with these requirements were small and the zero survival may not be an accurate reflection of survival in the population of patients with this requirement.
The high APACHE II and maximal MOD scores in our survivors indicate that they were suffering from severe critical illness and multi-organ failure and their survival was not a reflection of limited organ failure and low severity of illness. Interestingly, the maximal MOD score was higher in non-survivors than survivors. We believe this reflects the rapid demise of the non-survivors. The maximal MOD score is a well-established measure of multi-organ dysfunction developed by Marshall et al 12 and validated in our unit 13 . Patients are assigned a score of 0 to 24, based on the severity of cardiovascular, respiratory, renal, neurological, hepatic and haematological dysfunction. The maximum score in each organ system during the patient's ICU stay is noted and the maximal MOD score is calculated as the sum of these maximum scores. Scores were based on physiological values at a fixed time point each day and were not calculated if the patient was moribund 13 . Thus there would be a tendency to lower scores amongst those patients who die very rapidly.
The major limitation of our study was that it was a single-centre retrospective study with a relatively small cohort of patients. This is reflected in the relatively wide confidence intervals for probability of survival. Furthermore, only survival was examined and no data on quality of life were available. Therapy was withheld or withdrawn in 26 of the 64 patients and it is possible that, had therapy not been limited, the survival would have been higher. Conversely, as the frequency of limitation of therapy (41%) was lower than a previous estimate of the frequency in our unit (59%) 14 , it may be that the study cohort represents a sub-group who were treated more aggressively than usual. In view of these limitations, a prospective, ideally multi-centred, observational study is warranted to establish a more accurate estimate of the survival and quality of life of this group of patients. In the meantime our data may be useful in making informed decisions regarding the appropriateness of treating critically ill patients with high doses of noradrenaline.
Our retrospective study indicates that the survival of patients who require high-dose vasopressor therapy (combined noradrenaline and adrenaline >100 µg/min) is poor, with a hospital survival of 6.25%. It remains for individual clinicians, patients and their surrogates to decide whether use of high doses of vasopressor is appropriate given this low probability of survival.
